Replies to post #47202 on $heff's $tation of $tocks & $olid DD

[dumchit]

AMRN Jason Npododano talked to AMRN this was on his twitter

Jason Napodano, CFA

Ok - just spoke to $AMRN -->Mgt has not seen the final rejection letter yet, but was firm in their stance that the words "final rejection" are doubly misleading. Fist off, the letter is not "final", they will apeal. Secondly, there's no "rejection" of the IP. AMRN has filed "hundreds" of patents around MARINE and ANCHOR. This is just one of many. The issue is with data exclusivity. A company in Japan has previously studied the drug in 200-500mg population. MARINE was >500mg population. USPTO sees this as the "same" patients. AMRN disagrees, and will apeal. Long story short, there's nothing in this rejection that puts the IP at risk, still many applications pending and patents active, including applications around ANCHOR.

[rahrah]

AMRN---from another site, someone wrote: "the PTO said the application's claim weren't patentable because they amount to "double" patenting of claims cited in another patent aplication. The other patent application is pending and covers the composition of the drug".

[$heff]

AMRN...$11.75 AH Definitely one to watch from the sidelines with your money while this murky situation gets cleared up. It is not what AMRN believes they have or have not done but what is in the details with the USPTO. It is also what the market believes as well as potential partners. There is uncertainty here & we know that is not good for any company especially as they enter such a lucrative market with so much potential.